Fig. 8: There is limited immunotherapeutic efficacy in TNBC patients with elevated SNRNP200 levels.

a Overview of the I-SPY2 clinical trial (ClinicalTrials.gov: NCT01042379), which included 114 TNBC patients, with 29 receiving pembrolizumab plus chemotherapy and 85 receiving chemotherapy. b Bar chart illustrating SNRNP200 expression in 41 glycolytic TNBC patients with confirmed responses, categorized as pCR vs nonpCR. SNRNP200 expression was dichotomized by the median, and patient responses were stratified in both the immunotherapy and chemotherapy arms of the I-SPY2 clinical trial. c Expression of SNRNP200, normalized enrichment scores of MPS2-upregulated metabolic pathways, and proportions of representative infiltrating immune cells in the pembrolizumab group (MPS2, n = 15). d Overview of two scRNA-seq datasets, comprising a first cohort of 13 TNBC patients treated with pembrolizumab (BioKey study, ClinicalTrials.gov: NCT03197389) and a second cohort of 7 treatment-naïve TNBC patients (GSE176078). e Uniform manifold approximation and projection (UMAP) map of 70,190 cells color-coded for the indicated cell type. pDC plasmacytoid dendritic cell. PVLs perivascular-like cells. f UMAP map of 22,017 cancer cells grouped on the basis of AUCell values, with cells categorized as SG⁺ and SG⁻. g Proportion of SG⁺ cancer cells in patients who responded or did not respond to immunotherapy. h Heatmap depicting normalized enrichment scores of MPS2-upregulated metabolic pathways in the indicated cell types. i Schematic cartoon depicting the mechanism by which targeting SNRNP200 promotes an antitumor immune response in glycolytic tumors. For b, g, the data were analyzed using the chi-squared test (*P < 0.05; ***P < 0.001; ns not significant, P > 0.05).